Exicure, Inc. (NASDAQ:XCUR) Sees Significant Growth in Short Interest

Exicure, Inc. (NASDAQ:XCUR) saw a large increase in short interest in October. As of October 31st, there was short interest totalling 31,100 shares, an increase of 72.8% from the October 15th total of 18,000 shares. Based on an average daily volume of 1,030,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 4.7% of the shares of the stock are sold short.

Exicure Trading Down 15.2 %

XCUR opened at $2.73 on Thursday. The company’s 50 day moving average is $2.69 and its 200-day moving average is $1.26. The company has a market cap of $4.72 million, a P/E ratio of -0.62 and a beta of 1.28. Exicure has a 1-year low of $1.44 and a 1-year high of $6.00.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Insider Transactions at Exicure

In other Exicure news, major shareholder Co. Ltd. Dgp bought 237,223 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was purchased at an average cost of $3.00 per share, for a total transaction of $711,669.00. Following the completion of the purchase, the insider now directly owns 849,223 shares of the company’s stock, valued at approximately $2,547,669. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 3.90% of the stock is currently owned by insiders.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.